SCHEMBL15638342

SCHEMBL15638342

N#Cc1ccc(NC2CCC2)c(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.46
IRAK4 Q9NWZ3 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CISD1 Q9NZ45 1/20 0.42
MAP2K1 Q02750 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA13 Q8N1Q1 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
EPHX1 P07099 1/20 0.42
ALB P02768 1/20 0.42
CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946805 0.97 NPC1 (0.47) HCAR3IRAK4NPC1RAB9ACISD1
SCHEMBL7367462 0.89 HSP90AA1 (0.44) HCAR3MAP2K1ALBCDK2
SCHEMBL7367463 0.89 HSP90AA1 (0.44) HCAR3MAP2K1ALBCDK2
SCHEMBL15635242 0.89 MAP2K1 (0.48) HCAR3IRAK4NPC1RAB9ACISD1
SCHEMBL15635836 0.85 YAP1 (0.56) IRAK4NPC1RAB9AEPHX1ALDH1A1
SCHEMBL6945540 0.82 YAP1 (0.59) IRAK4NPC1RAB9AEPHX1ALDH1A1
SCHEMBL15635524 0.78 IRAK4 (0.41) IRAK4NPC1RAB9A
SCHEMBL15635527 0.78 HCAR3 (0.49) HCAR3NPC1RAB9ACISD1CA12
SCHEMBL17363152 0.77 YAP1 (0.47) IRAK4NPC1RAB9AMAP2K1EPHX1
SCHEMBL27437365 0.76 KDM4E (0.50) HCAR3IRAK4NPC1RAB9AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903965-B1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS ORION CORP (FI) 2017-03-01 EP disclosed
US-9533952-B2 N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists ORION CORPORATION (FI) 2017-01-03 US disclosed
US-20150376130-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS Orlon Corporation (FI) 2015-12-31 US disclosed
EP-2903965-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS Orion Corporation (FI) 2015-08-12 EP disclosed
WO-2014053694-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS ORION CORPORATION (FI) 2014-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376130-A1 N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 HCAR3 143/4885IRAK4 2748/4885NPC1 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.